Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 5/2012

Open Access 01-09-2012 | Original Article

Prevalence of symptoms in female Fabry disease patients: a case-control survey

Authors: Machtelt G. Bouwman, Saskia M. Rombach, Erica Schenk, Annelies Sweeb, Frits A. Wijburg, Carla E. M. Hollak, Gabor E. Linthorst

Published in: Journal of Inherited Metabolic Disease | Issue 5/2012

Login to get access

Abstract

Background

Fabry disease (FD) is an X-linked lysosomal storage disorder, caused by a deficiency of α-galactosidase A. Several studies demonstrated that heterozygotes have symptoms such as acroparesthesia, abdominal pain and chronic fatigue. However, as these symptoms are aspecific and relatively common in the general population, it is important to compare the prevalence of these symptoms with an appropriate control group. The aim of this study was to explore the prevalence of signs and symptoms in FD females in comparison to a control group.

Methods

FD females and age-matched controls were approached to complete a questionnaire. This questionnaire was developed by the Dutch Fabry patient organisation (Fabry Support en Informatie Groep Nederland, FSIGN) with input from Fabry expert-physicians from the AMC. We compared the prevalence symptoms using Pearson’s chi-square test. Bonferroni correction was used to correct for multiple comparisons.

Results

A total of 63 heterozygotes and 52 controls completed the questionnaire. Many symptoms were also common in controls. Yet, fatigue, palpitations, pains in hands and feet, joint pain, dizziness, loss of libido and proteinuria during pregnancy were more common in Fabry females (all p < 0.001).

Conclusion

In addition to acroparesthesia - fatigue, palpitations, dizziness, proteinuria during pregnancy, libido loss and joint pain are more prevalent in FD females as compared to a control group. Although, these symptoms are present in a significant proportion of normal controls they deserve further attention by treating physicians to better understand their significance, treatment and relationship with FD.
Literature
go back to reference Bouwman MG, Hollak CE, van den Bergh Weerman MA, Wijburg FA, Linthorst GE (2010) Analysis of placental tissue in Fabry disease with and without enzyme replacement therapy. Placenta 31(4):344–346PubMedCrossRef Bouwman MG, Hollak CE, van den Bergh Weerman MA, Wijburg FA, Linthorst GE (2010) Analysis of placental tissue in Fabry disease with and without enzyme replacement therapy. Placenta 31(4):344–346PubMedCrossRef
go back to reference Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M (2006) Natural history of Fabry disease in females in the Fabry outcome survey. J Med Genet 43(4):347–352PubMedCentralPubMedCrossRef Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M (2006) Natural history of Fabry disease in females in the Fabry outcome survey. J Med Genet 43(4):347–352PubMedCentralPubMedCrossRef
go back to reference Desnick RJ, Ioannou YA, Eng CM (2001) A-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, NewYork, pp 3733–3774 Desnick RJ, Ioannou YA, Eng CM (2001) A-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, NewYork, pp 3733–3774
go back to reference Galanos J, Nicholls K, Grigg L, Kiers L, Crawford A, Becker G (2002) Clinical features of Fabry's disease in Australian patients. Intern Med J 32(12):575–584PubMedCrossRef Galanos J, Nicholls K, Grigg L, Kiers L, Crawford A, Becker G (2002) Clinical features of Fabry's disease in Australian patients. Intern Med J 32(12):575–584PubMedCrossRef
go back to reference Germain DP, Avan P, Chassaing A, Bonfils P (2003) Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 2002 October 11;3:10.Guffon N. Clinical presentation in female patients with Fabry disease. J Med Genet 40(4):e38CrossRef Germain DP, Avan P, Chassaing A, Bonfils P (2003) Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 2002 October 11;3:10.Guffon N. Clinical presentation in female patients with Fabry disease. J Med Genet 40(4):e38CrossRef
go back to reference Germain DP, Bruneval P, Tran TC, Balouet P, Richalet B, Benistan K (2010) Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: a case report. Eur J Med Genet 53(2):111–112PubMedCrossRef Germain DP, Bruneval P, Tran TC, Balouet P, Richalet B, Benistan K (2010) Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: a case report. Eur J Med Genet 53(2):111–112PubMedCrossRef
go back to reference Gupta S, Ries M, Kotsopoulos S, Schiffmann R (2005) The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 84(5):261–268CrossRef Gupta S, Ries M, Kotsopoulos S, Schiffmann R (2005) The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 84(5):261–268CrossRef
go back to reference Kalkum G, Macchiella D, Reinke J, Kolbl H, Beck M (2009) Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease. Eur J Obstet Gynecol Reprod Biol 144(1):92–93PubMedCrossRef Kalkum G, Macchiella D, Reinke J, Kolbl H, Beck M (2009) Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease. Eur J Obstet Gynecol Reprod Biol 144(1):92–93PubMedCrossRef
go back to reference Kobayashi M, Ohashi T, Sakuma M, Ida H, Eto Y (2008) Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease. J Inherit Metab Dis Kobayashi M, Ohashi T, Sakuma M, Ida H, Eto Y (2008) Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease. J Inherit Metab Dis
go back to reference Macdermot KD, Holmes A, Miners AH (2001a) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38(11):769–775PubMedCentralPubMedCrossRef Macdermot KD, Holmes A, Miners AH (2001a) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38(11):769–775PubMedCentralPubMedCrossRef
go back to reference Macdermot KD, Holmes A, Miners AH (2001b) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38(11):750–760PubMedCentralPubMedCrossRef Macdermot KD, Holmes A, Miners AH (2001b) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38(11):750–760PubMedCentralPubMedCrossRef
go back to reference Mehta A, Ricci R, Widmer U, Dehout F, de Garcia LA, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Invest 34(3):236–242PubMedCrossRef Mehta A, Ricci R, Widmer U, Dehout F, de Garcia LA, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Invest 34(3):236–242PubMedCrossRef
go back to reference Parent E, Wax JR, Smith W, Blaszyk H, Pinette MG, Cartin A, Blackstone J (2010) Fabry disease complicating pregnancy. J Matern Fetal Neonatal Med 23(10):1253–1256PubMedCrossRef Parent E, Wax JR, Smith W, Blaszyk H, Pinette MG, Cartin A, Blackstone J (2010) Fabry disease complicating pregnancy. J Matern Fetal Neonatal Med 23(10):1253–1256PubMedCrossRef
go back to reference Politei JM (2010) Treatment with agalsidase beta during pregnancy in Fabry disease. J Obstet Gynaecol Res 36(2):428–429PubMedCrossRef Politei JM (2010) Treatment with agalsidase beta during pregnancy in Fabry disease. J Obstet Gynaecol Res 36(2):428–429PubMedCrossRef
go back to reference Schiffmann R (2001) Natural history of Fabry disease in males: preliminary observations. J Inherit Metab Dis 24(Suppl 2):15–17PubMedCrossRef Schiffmann R (2001) Natural history of Fabry disease in males: preliminary observations. J Inherit Metab Dis 24(Suppl 2):15–17PubMedCrossRef
go back to reference Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24(7):2102–2111PubMedCentralPubMedCrossRef Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24(7):2102–2111PubMedCentralPubMedCrossRef
go back to reference Simon JA (2010) Low sexual desire–is it all in her head? Pathophysiology, diagnosis, and treatment of hypoactive sexual desire disorder. Postgrad Med 122(6):128–136PubMedCrossRef Simon JA (2010) Low sexual desire–is it all in her head? Pathophysiology, diagnosis, and treatment of hypoactive sexual desire disorder. Postgrad Med 122(6):128–136PubMedCrossRef
go back to reference Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, Mannens MM, Aerts JM, Hollak CE (2007) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30(1):68–78PubMedCrossRef Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, Mannens MM, Aerts JM, Hollak CE (2007) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30(1):68–78PubMedCrossRef
go back to reference Wang RY, Lelis A, Mirocha J, Wilcox WR (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9(1):34–45PubMedCrossRef Wang RY, Lelis A, Mirocha J, Wilcox WR (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9(1):34–45PubMedCrossRef
go back to reference Wendt S, Whybra C, Kampmann C, Teichmann E, Beck M (2005) Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. J Inherit Metab Dis 28(5):787–788PubMedCrossRef Wendt S, Whybra C, Kampmann C, Teichmann E, Beck M (2005) Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. J Inherit Metab Dis 28(5):787–788PubMedCrossRef
go back to reference Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, Bruhl K, Gal A, Bunge S, Beck M (2001) Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24(7):715–724PubMedCrossRef Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, Bruhl K, Gal A, Bunge S, Beck M (2001) Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24(7):715–724PubMedCrossRef
go back to reference Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93(2):112–128PubMedCrossRef Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93(2):112–128PubMedCrossRef
Metadata
Title
Prevalence of symptoms in female Fabry disease patients: a case-control survey
Authors
Machtelt G. Bouwman
Saskia M. Rombach
Erica Schenk
Annelies Sweeb
Frits A. Wijburg
Carla E. M. Hollak
Gabor E. Linthorst
Publication date
01-09-2012
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 5/2012
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-011-9447-9

Other articles of this Issue 5/2012

Journal of Inherited Metabolic Disease 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.